Stroke in essential thrombocythemia

Éva Pósfai, Imelda Marton, Anita Szoke, Zita Borbényi, L. Vécsei, Angéla Csomor, K. Sas

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Our aim was to assess the incidence and the special characteristics of stroke, as a severe complication of patients diagnosed with essential thrombocythemia (ET). Methods A retrospective analysis was carried out on 102 patients with ET enrolled and analyzed from the period between 1999 and 2012. Patients with one or more strokes were selected. The characteristics of stroke events, the medication, and the median platelet counts were revised. Results One or more stroke events were revealed in 11 cases (4 males and 7 females) with a median age of 67 years [range: 45-82 years]. The median platelet count at hematological diagnosis was 658 × 109/L [range: 514-1157 × 109/L], while during the time of stroke it was 450 × 109/L [range: 320-885 × 109/L]. The median follow-up of the patients with stroke was 60 months [range: 19-127 months]. At the time of the stroke, almost all the patients (8/11 cases, 73%) were already on anti-platelet therapy, alone or in combination with cytoreductive therapy (e.g. hydroxyurea). Brain imaging modalities in most cases demonstrated periventricular and/or subcortical and/or basal ganglia lacunes or confluent chronic white matter ischemic lesions in all cerebral arterial regions. Most patients (9/11; 82%) presented at least two serious conventional vascular risk factors, which may have influenced both the clinical course and the morphologic alterations. No correlation was found between the platelet count and the occurrence of stroke. Conclusion Our findings lead us to suppose that ET may be regarded as a risk factor for stroke (mainly of ischemic, small-vessel type), and the early diagnosis and the personalized management of the patient's global vascular risk in the treatment of ET may promote the prevention of further cerebrovascular events.

Original languageEnglish
Pages (from-to)260-262
Number of pages3
JournalJournal of the Neurological Sciences
Volume336
Issue number1-2
DOIs
Publication statusPublished - Jan 15 2014

Fingerprint

Essential Thrombocythemia
Stroke
Platelet Count
Hydroxyurea
Basal Ganglia
Neuroimaging
Blood Vessels
Early Diagnosis
Therapeutics
Blood Platelets

Keywords

  • Cerebrovascular events
  • Essential thrombocythemia
  • JAK2 V617F mutation
  • Myeloproliferative neoplasm
  • Platelets
  • Risk factors
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Pósfai, É., Marton, I., Szoke, A., Borbényi, Z., Vécsei, L., Csomor, A., & Sas, K. (2014). Stroke in essential thrombocythemia. Journal of the Neurological Sciences, 336(1-2), 260-262. https://doi.org/10.1016/j.jns.2013.10.016

Stroke in essential thrombocythemia. / Pósfai, Éva; Marton, Imelda; Szoke, Anita; Borbényi, Zita; Vécsei, L.; Csomor, Angéla; Sas, K.

In: Journal of the Neurological Sciences, Vol. 336, No. 1-2, 15.01.2014, p. 260-262.

Research output: Contribution to journalArticle

Pósfai, É, Marton, I, Szoke, A, Borbényi, Z, Vécsei, L, Csomor, A & Sas, K 2014, 'Stroke in essential thrombocythemia', Journal of the Neurological Sciences, vol. 336, no. 1-2, pp. 260-262. https://doi.org/10.1016/j.jns.2013.10.016
Pósfai É, Marton I, Szoke A, Borbényi Z, Vécsei L, Csomor A et al. Stroke in essential thrombocythemia. Journal of the Neurological Sciences. 2014 Jan 15;336(1-2):260-262. https://doi.org/10.1016/j.jns.2013.10.016
Pósfai, Éva ; Marton, Imelda ; Szoke, Anita ; Borbényi, Zita ; Vécsei, L. ; Csomor, Angéla ; Sas, K. / Stroke in essential thrombocythemia. In: Journal of the Neurological Sciences. 2014 ; Vol. 336, No. 1-2. pp. 260-262.
@article{4fd5edc7a2604e7fb792951dbd4d1ade,
title = "Stroke in essential thrombocythemia",
abstract = "Background Our aim was to assess the incidence and the special characteristics of stroke, as a severe complication of patients diagnosed with essential thrombocythemia (ET). Methods A retrospective analysis was carried out on 102 patients with ET enrolled and analyzed from the period between 1999 and 2012. Patients with one or more strokes were selected. The characteristics of stroke events, the medication, and the median platelet counts were revised. Results One or more stroke events were revealed in 11 cases (4 males and 7 females) with a median age of 67 years [range: 45-82 years]. The median platelet count at hematological diagnosis was 658 × 109/L [range: 514-1157 × 109/L], while during the time of stroke it was 450 × 109/L [range: 320-885 × 109/L]. The median follow-up of the patients with stroke was 60 months [range: 19-127 months]. At the time of the stroke, almost all the patients (8/11 cases, 73{\%}) were already on anti-platelet therapy, alone or in combination with cytoreductive therapy (e.g. hydroxyurea). Brain imaging modalities in most cases demonstrated periventricular and/or subcortical and/or basal ganglia lacunes or confluent chronic white matter ischemic lesions in all cerebral arterial regions. Most patients (9/11; 82{\%}) presented at least two serious conventional vascular risk factors, which may have influenced both the clinical course and the morphologic alterations. No correlation was found between the platelet count and the occurrence of stroke. Conclusion Our findings lead us to suppose that ET may be regarded as a risk factor for stroke (mainly of ischemic, small-vessel type), and the early diagnosis and the personalized management of the patient's global vascular risk in the treatment of ET may promote the prevention of further cerebrovascular events.",
keywords = "Cerebrovascular events, Essential thrombocythemia, JAK2 V617F mutation, Myeloproliferative neoplasm, Platelets, Risk factors, Stroke",
author = "{\'E}va P{\'o}sfai and Imelda Marton and Anita Szoke and Zita Borb{\'e}nyi and L. V{\'e}csei and Ang{\'e}la Csomor and K. Sas",
year = "2014",
month = "1",
day = "15",
doi = "10.1016/j.jns.2013.10.016",
language = "English",
volume = "336",
pages = "260--262",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Stroke in essential thrombocythemia

AU - Pósfai, Éva

AU - Marton, Imelda

AU - Szoke, Anita

AU - Borbényi, Zita

AU - Vécsei, L.

AU - Csomor, Angéla

AU - Sas, K.

PY - 2014/1/15

Y1 - 2014/1/15

N2 - Background Our aim was to assess the incidence and the special characteristics of stroke, as a severe complication of patients diagnosed with essential thrombocythemia (ET). Methods A retrospective analysis was carried out on 102 patients with ET enrolled and analyzed from the period between 1999 and 2012. Patients with one or more strokes were selected. The characteristics of stroke events, the medication, and the median platelet counts were revised. Results One or more stroke events were revealed in 11 cases (4 males and 7 females) with a median age of 67 years [range: 45-82 years]. The median platelet count at hematological diagnosis was 658 × 109/L [range: 514-1157 × 109/L], while during the time of stroke it was 450 × 109/L [range: 320-885 × 109/L]. The median follow-up of the patients with stroke was 60 months [range: 19-127 months]. At the time of the stroke, almost all the patients (8/11 cases, 73%) were already on anti-platelet therapy, alone or in combination with cytoreductive therapy (e.g. hydroxyurea). Brain imaging modalities in most cases demonstrated periventricular and/or subcortical and/or basal ganglia lacunes or confluent chronic white matter ischemic lesions in all cerebral arterial regions. Most patients (9/11; 82%) presented at least two serious conventional vascular risk factors, which may have influenced both the clinical course and the morphologic alterations. No correlation was found between the platelet count and the occurrence of stroke. Conclusion Our findings lead us to suppose that ET may be regarded as a risk factor for stroke (mainly of ischemic, small-vessel type), and the early diagnosis and the personalized management of the patient's global vascular risk in the treatment of ET may promote the prevention of further cerebrovascular events.

AB - Background Our aim was to assess the incidence and the special characteristics of stroke, as a severe complication of patients diagnosed with essential thrombocythemia (ET). Methods A retrospective analysis was carried out on 102 patients with ET enrolled and analyzed from the period between 1999 and 2012. Patients with one or more strokes were selected. The characteristics of stroke events, the medication, and the median platelet counts were revised. Results One or more stroke events were revealed in 11 cases (4 males and 7 females) with a median age of 67 years [range: 45-82 years]. The median platelet count at hematological diagnosis was 658 × 109/L [range: 514-1157 × 109/L], while during the time of stroke it was 450 × 109/L [range: 320-885 × 109/L]. The median follow-up of the patients with stroke was 60 months [range: 19-127 months]. At the time of the stroke, almost all the patients (8/11 cases, 73%) were already on anti-platelet therapy, alone or in combination with cytoreductive therapy (e.g. hydroxyurea). Brain imaging modalities in most cases demonstrated periventricular and/or subcortical and/or basal ganglia lacunes or confluent chronic white matter ischemic lesions in all cerebral arterial regions. Most patients (9/11; 82%) presented at least two serious conventional vascular risk factors, which may have influenced both the clinical course and the morphologic alterations. No correlation was found between the platelet count and the occurrence of stroke. Conclusion Our findings lead us to suppose that ET may be regarded as a risk factor for stroke (mainly of ischemic, small-vessel type), and the early diagnosis and the personalized management of the patient's global vascular risk in the treatment of ET may promote the prevention of further cerebrovascular events.

KW - Cerebrovascular events

KW - Essential thrombocythemia

KW - JAK2 V617F mutation

KW - Myeloproliferative neoplasm

KW - Platelets

KW - Risk factors

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84892585102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892585102&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2013.10.016

DO - 10.1016/j.jns.2013.10.016

M3 - Article

C2 - 24183283

AN - SCOPUS:84892585102

VL - 336

SP - 260

EP - 262

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -